Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05916287
Other study ID # 2020PI129
Secondary ID 2021-A00449-32
Status Recruiting
Phase N/A
First received
Last updated
Start date July 13, 2023
Est. completion date July 13, 2027

Study information

Verified date August 2023
Source Central Hospital, Nancy, France
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Stanislas Cohort is a monocentric familial longitudinal cohort originally comprised of 1006 families consisting of two parents and at least two biological children and deemed healthy, recruited in 1993-1995 at the Centre for Preventive Medicine of Nancy. This cohort was established with the primary objective of investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases. The 5th visit of the STANISLAS Cohort will allow a better evaluation of the cardiovascular ageing of the population and the transition toward cardiovascular or renal diseases in relation with their genetic profile and environment.


Description:

The main objective of the STANISLAS cohort is to identify the factors associated with cardiovascular aging (assessed through the study of the degradation of morphological and functional parameters of the heart and vascular systems). Data (clinical, biological, morphological, genetic and lifestyle) from previous visits (the first having been initiated in the mid-1990s) will be considered as exposure and / or adjustment variables. The exposure variables of interest will be: - The components of metabolic syndrome (MS), - Genetic determinants, through an approach of family segregation and candidate genes, - Multi-omic biomarkers analyzed from the biological collection of the first assessments of the cohort - Food intake, nutrition and eating behavior The secondary objectives are - Identify the factors associated with a degradation of renal parameters (renal function and proteinuria). - Identify the factors associated with a degradation of metabolic parameters. - To assess the association between SARS-CoV-2 infection (questionnaire and serological approach) and cardiovascular and renal parameters - Identify factors associated with the occurrence of clinical cardiovascular events. - Association between Covid 19 events and general disabling symptoms - Complete the cohort's biological collection for future biomarker assays related to previous objectives


Recruitment information / eligibility

Status Recruiting
Enrollment 3000
Est. completion date July 13, 2027
Est. primary completion date July 13, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - aged over 18 - Person who participated in the Stanislas Cohort - Person affiliated to a social security scheme or beneficiary of such a scheme - Person having received complete information on the organization of the research and having signed an informed consent Exclusion Criteria: - Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric treatment under Articles L. 3212-1 and L. 3213-1 - Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code: - Pregnant woman, parturient or nursing mother - Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) - Person of full age unable to express consent

Study Design


Intervention

Biological:
Blood and urine samples
Blood and urine samples
Genetic:
Blood samples
Blood samples
Other:
Cardiovascular assessment
Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).
Behavioral:
Dietary intake
Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire
Other:
Anthropometric parameters
Measurement of height, weight, abdominal circumference, hip circumference, arm circumference
Hemodynamic parameters
Systolic pressure index measurement
Hemodynamic parameters
Heart rate measurements, blood pressure measurements, orthostatic BP measurements
Hemodynamic parameters
Blood pressure measurements by "unattended BP" monitor over 5 min
Hemodynamic parameters
Electrocardiogram
Behavioral:
Assessment of compliance with antihypertensive treatments for treated participants
EVALOBS scale and compliance questionnaire
Other:
Ambulatory 24 hours measurment of blood pressure
For the first 100 patients willing to participate
Biological:
24 hours urinary collection
For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick
Other:
General questionnaires
Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)
Women specific questionnaire
Women specific questionnaire
Behavioral:
Women specific questionnaire
Women specific questionnaire
Diagnostic Test:
NYHA dyspnea questionnaire
Determination of NYHA class.
Behavioral:
Anxiety questionnaire
Assessment of anxiety
Epworth Sleepiness Scale
sleep quality assessment
Other:
A questionnaire on the "perception of the management of cardiovascular risk factors"
Patient's evaluation of cardiovascular risk factors by the health system
Behavioral:
A questionnaire on eating behaviors
Assessment of eating behaviors
A questionnaire on eating habits to determine consumer profiles
Assessement of eating habit to create a consumer profile
Dietary Supplement:
A questionnaire on food supplements use
Evaluation od food supplements intake
Other:
SARS-CoV-2 Infection Questionnaire
SARS-CoV-2 Infection Questionnaire
Instantaneous expired air analysis
Carbon monoxyde analysis in expired air
Biological:
Capillary sampling
Capillary sampling for pollutant analysis (Optional)

Locations

Country Name City State
France CHRU de Nancy VandÅ“uvre-lès-Nancy Lorraine

Sponsors (1)

Lead Sponsor Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Indexed left ventricular mass measured by echocardiography Baseline
Primary Left ventricular volume measured by echocardiography Baseline
Primary Tissue doppler imaging e' wave measured by echocardiography Baseline
Primary Ratio E/e' measured by echocardiography Baseline
Primary Left atrial volume measured by echocardiography Baseline
Primary Pulmonary congestion evaluated by lung ultrasound Baseline
Primary Pulse wave velocity measured by Sphygmocor and Complior Analyse Baseline
Primary Carotid intima media thickness measured by echotracking Baseline
Primary Central blood pressure Baseline
Secondary Estimation of the glomerular filtration rate (CKD-EPI formula) Composite endpoint of degradation of renal function (With outcome 11) Baseline
Secondary Proteinuria (on sample) Composite endpoint of degradation of renal function (With outcome 10) Baseline
Secondary Blood glucose Composite endpoint of degradation of metabolic parameters (With outcome 13 and 14) Baseline
Secondary Change in HbA1C Composite endpoint of degradation of metabolic parameters (With outcome 12 and 14) Baseline
Secondary Change in lipid parameters (LDL and HDL cholesterol) Composite endpoint of degradation of metabolic parameters (With outcome 12 and 13) Baseline
Secondary Occurrence of the following clinical CV events: Hospitalization for HF, HF not requiring hospitalization, Atrial fibrillation, Acute coronary syndrome, Coronary artery disease, Hypertension (requiring introduction of drug treatment), Stroke Baseline
Secondary General symptoms persisting beyond 8 weeks after SARS-CoV-2 infection such as: disabling asthenia, disabling dyspnea, cardiothoracic signs, arthromyalgia, neurocognitive disorders or anosmia Baseline
Secondary Results of future relevant biomarker assays Biomarkers on the cardiovascular field, measured on biological collection and dependant on the progress of knowledge and technology Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)